Published in

Elsevier, Kidney International, 1(101), p. 174-184, 2022

DOI: 10.1016/j.kint.2021.09.005

Links

Tools

Export citation

Search in Google Scholar

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Journal article published in 2022 by Hiddo J. L. Heerspink ORCID, David Cherney, Douwe Postmus, Bergur V. Stefánsson, Glenn M. Chertow, Jamie P. Dwyer ORCID, Tom Greene, Mikhail Kosiborod, Anna Maria Langkilde, John J. V. McMurray, Ricardo Correa-Rotter, Peter Rossing ORCID, C. David Sjöström, Robert D. Toto, David C. Wheeler and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO